Table 3 Summary of multivariate analyses

From: Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

Parameters

Overall response

Comparison

Adjusted P-value

CD8+ Teff density

1 week before RTCT

PR vs non-PR

0.99

EOT visit

CR vs non-CR

0.0002

CD4+ Teff density

1 week before RTCT

PR vs non-PR

0.72

EOT visit

CR vs non-CR

0.86

CD8+ Teff/Treg ratio

1 week before RTCT

PR vs non-PR

0.057

EOT visit

CR vs non-CR

0.12

Ki67+CD8+ Teff density

1 week before RTCT

PR vs non-PR

0.056

EOT visit

CR vs non-CR

0.0009

Ki67+CD4+ Teff density

1 week before RTCT

PR vs non-PR

0.14

EOT visit

CR vs non-CR

0.012

Ki67+CD8+ Teff/Treg ratio

1 week before RTCT

PR vs non-PR

0.95

EOT visit

CR vs non-CR

0.0009

HOT score

1 week before RTCT

PR vs non-PR

0.943

EOT visit

CR vs non-CR

0.9894

  1. CR complete response, EOT end-of-treatment, PR partial response, RTCT chemoradiation, Teff effector T cells, Treg regulatory T cells.
  2. Associations were evaluated using multivariable analyses. All tests were two‑sided. Reported adjusted P-values were calculated using the Tukey–Kramer procedure; bold font denotes P-values < 0.1.
Back to article page